Table 4.
Reported series of patients treated with local treatment for breast cancer liver metastases.
| Reference | No. of patients/lesions | Local treatment LM | Mean tumor diameter cm (range) | Local control | PFS (month) | OS (month) |
| Cianni et al,[14] | 52/ | RE | NA | 90% | NA | 11.5 |
| Carrafiello et al,[15] | 13/21 | RFA | 3.5 (0–70) | 66.7% | NA | 10.9 |
| Meloni et al,[6] | 52/87 | RFA | 2.5(0.7–5.0) | 97% | NA | 29.9 |
| Jakobs et al,[7] | 43/111 | RFA | 2.0 (0.5–8.5) | NA | 10.5 | 58.6 |
| Iannitti et al,[16] | 87/224 | WMA | 3.6 (0.5–9) | 97.3% | NA | 47% alive at 19 months |
| Lin et al,[17] | 23/ | TACE | NA | 83% | 8.0 | 17.0 |
| Eichler et al,[18] | 41/ | TACE | NA | 46.3% | 3.3 | 10.2 |
| Onal et al,[19] | 22/29 | SBRT | 2.2 (1.4–6.0) | 1 year 100%2 year 88% | 1 year 38%2 year 8% | 1 year 85%2 year 57% |
| Weinrich et al[20] | 29/56 | S | NA | NA | NA | 1 year 86% |
| Lubrano et al[21] | 16/22 | S | 3.5 (1.0–10) | NA | NA | 42 |
| Zhang et al[10] | 17/39 | CA | 4.0 (2.5–7.5) | 3 month 84% | NA | 1 year 70.6% |